TENAX (TENX) Director Declan Doogan Buys 53,000 Shares

What Happened
Declan Doogan, a director of Tenax Therapeutics, purchased 53,000 shares of TENX on 2026-09-16 at $1.92 per share, for a total cost of approximately $101,760. This was a purchase (Form 4 code P), not a sale or option exercise.

Key Details

• Transaction date: 2026-09-16
• Transaction type: Open-market purchase (SEC code P)
• Price per share: $1.92
• Shares purchased: 53,000
• Total value: ~$101,760
• Shares owned after transaction: Not reported on the Form 4 filing
• Footnotes / plans disclosed: None noted (no 10b5‑1 plan, tax withholding, or other footnotes disclosed)
• Filing timeliness: Form 4 filed 2026-09-17 (filed the next day; appears timely)

Context
Insider purchases can be informative to investors because they show an insider putting cash into the company, but a single purchase of this size (~$102k) is a modest stake and not definitive evidence of future performance. Retail investors may want to watch for additional insider activity, recent company news, clinical or regulatory updates, and overall financials before drawing conclusions.